Department of Neurosurgery, Fujita Health University, Toyoake, Aichi, Japan.
Department of Neurosurgery, Fujita Health University, Banbuntane Hotokukai Hospital, Aichi, Japan.
World Neurosurg. 2019 Jun;126:e1042-e1049. doi: 10.1016/j.wneu.2019.03.040. Epub 2019 Mar 13.
c-Met has been shown to be associated with tumor growth in several human cancers. This study aims to evaluate the correlation between the c-Met expression and histopathologic/clinical characteristics.
A total of 153 patients with histologically defined World Health Organization grade II-IV diffuse astrocytic and oligodendroglial tumors were analyzed.
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. Furthermore, it was correlated with overall survival in AO, oligodendroglial tumors, DA, IDH-mutant, DA, IDH-wildtype, and glioblastoma, IDH-wildtype, and tend to be correlated with overall survival in IDH-mutant lower-grade astrocytic tumors.
c-Met expression was revealed to be a useful marker for prognosis prediction in IDH-mutant lower-grade gliomas and glioblastoma, IDH-wildtype, representing a new independent prognostic marker that can be easily measured.
c-Met 已被证明与几种人类癌症的肿瘤生长有关。本研究旨在评估 c-Met 表达与组织病理学/临床特征之间的相关性。
对 153 例经组织学定义的 II-IV 级弥漫性星形细胞瘤和少突胶质细胞瘤患者进行分析。
对于每种组织病理学诊断，c-Met 表达阳性的病例数和阳性率如下：少突胶质细胞瘤，IDH 突变，1p19q 缺失（OD）：16 例，6.3%；间变性少突胶质细胞瘤，IDH 突变，1p19q 缺失（AO）：11 例，36.4%；弥漫性星形细胞瘤（DA），IDH 突变：21 例，28.6%；间变性星形细胞瘤（AA），IDH 突变：15 例，20%；胶质母细胞瘤，IDH 突变：2 例，100%；DA，IDH 野生型：9 例，33.3%；AA，IDH 野生型：20 例，30.0%；胶质母细胞瘤，IDH 野生型：59 例，52.5%。c-Met 表达与少突胶质细胞瘤和胶质母细胞瘤 IDH 野生型的无进展生存期相关。此外，它与 AO、少突胶质细胞瘤、DA、IDH 突变、DA、IDH 野生型和胶质母细胞瘤 IDH 野生型的总生存期相关，并且与 IDH 突变的低级星形细胞瘤的总生存期相关。
c-Met 表达被证明是 IDH 突变的低级胶质瘤和胶质母细胞瘤 IDH 野生型预后预测的有用标志物，代表了一种新的独立的预后标志物，易于测量。
